<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A study was undertaken to investigate the suitability of using a high affinity (Kd = 1.1 nM) anti-CD45 monoclonal antibody for delivering the high energy <z:chebi fb="4" ids="10545">beta-particle</z:chebi> emitting isotope (90)Y to lymphohematopoietic target cells in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>The antibody, AHN-12, recognized the tyrosine phosphatase CD45 expressed on the surface of <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant hematopoietic cells and studies showed that it reacted with both CD45-expressing <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood cells and <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells from patients </plain></SENT>
<SENT sid="2" pm="."><plain>The antibody was readily labeled with (90)Y using the highly stable chelate 1B4M-<z:chebi fb="0" ids="35739">DTPA</z:chebi> and the radioimmunoconjugate was designated (90)Y-anti-CD45 </plain></SENT>
<SENT sid="3" pm="."><plain>The agent selectively bound to CD45(+) B cell line Daudi, but not CD45(-) control cells and significantly (p = 0.007) more bound to Daudi <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> growing in athymic <z:mp ids='MP_0003815'>nude</z:mp> mice than did a control non-reactive antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, biodistribution data correlated well to an anti-Daudi effect observed against established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="5" pm="."><plain>The effect was dose dependent and irreversible with the best results in mice receiving a single dose of 137 microCi (90)Y-anti-CD45 </plain></SENT>
<SENT sid="6" pm="."><plain>These mice displayed a significantly (p &lt; 0.0095) better anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effect than a control (90)Y-labeled antibody and survived over 135 days with no evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Histology studies showed no significant injury to kidney, liver, or small intestine even at 254 microCi, the highest dose tested </plain></SENT>
<SENT sid="8" pm="."><plain>Because radiolabeled anti-CD45 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data indicate that this agent may be used to improve treatment of <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, particularly <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, when combined with hematopoietic stem cell transplantation in a future clinical trial </plain></SENT>
</text></document>